Gastroenterology · Hepatobiliary Disease
The facts most likely to be tested
Primary Biliary Cholangitis is an autoimmune destruction of intrahepatic bile ducts that primarily affects middle-aged women.
The most specific serologic marker for diagnosis is the presence of anti-mitochondrial antibodies (AMA).
Patients classically present with insidious onset of fatigue and pruritus that is often worse at night.
Physical examination frequently reveals hepatomegaly, jaundice, and xanthelasma due to chronic cholestasis.
Laboratory findings demonstrate a cholestatic pattern characterized by an elevated alkaline phosphatase (ALP) and elevated GGT.
First-line pharmacologic therapy is ursodeoxycholic acid (UDCA), which slows disease progression and improves survival.
Associated conditions include other autoimmune disorders such as Sjogren syndrome, Hashimoto thyroiditis, and metabolic bone disease.
Vignette unlocked
A 48-year-old woman presents to the clinic complaining of a 4-month history of severe, generalized pruritus that is worse at night and persistent fatigue. She denies alcohol use, abdominal pain, or recent travel. Physical examination is significant for xanthelasma around the eyelids and mild hepatomegaly. Laboratory studies reveal an elevated alkaline phosphatase of 450 U/L, normal bilirubin, and normal transaminases. An anti-mitochondrial antibody (AMA) test is positive.
What is the most appropriate initial pharmacologic treatment for this patient?
Ursodeoxycholic acid
The patient's presentation of pruritus, elevated ALP, and positive AMA is diagnostic for Primary Biliary Cholangitis, for which ursodeoxycholic acid is the first-line treatment to delay disease progression.
Full handout
High yield triage
Etiology / Epidemiology
Autoimmune destruction of intrahepatic bile ducts primarily in middle-aged women.
Clinical Manifestations
Insidious onset of pruritus and fatigue; xanthomas and xanthelasmas are classic.
Diagnosis
Anti-mitochondrial antibody (AMA) is the hallmark; liver biopsy confirms if AMA is negative.
Treatment
Ursodeoxycholic acid is the first-line therapy; liver transplant for end-stage disease.
Prognosis
Risk of cirrhosis and hepatocellular carcinoma; monitor with ultrasound every 6 months.
Full handout
Epidemiology & Etiology
Affects women 30–65 years old with a strong female-to-male ratio of 9:1. It is an autoimmune condition characterized by T-cell mediated destruction of small intrahepatic bile ducts. Frequently associated with other autoimmune conditions like Sjogren syndrome and Hashimoto thyroiditis.
Pertinent Anatomy
Targets the interlobular bile ducts within the liver parenchyma. Destruction leads to cholestasis, bile acid accumulation, and eventual portal fibrosis.
Pathophysiology
Chronic cholestasis results from the progressive destruction of the bile duct epithelium. Accumulation of toxic bile acids causes hepatocyte injury, leading to inflammation and fibrosis. Over time, this progresses to biliary cirrhosis and portal hypertension.
Clinical Manifestations
Patients often present with pruritus (worse at night) and fatigue as the earliest symptoms. Physical exam may reveal jaundice, hepatomegaly, and hyperpigmentation. Late-stage findings include portal hypertension, ascites, and esophageal varices.
Diagnosis
Diagnosis requires two of three: elevated alkaline phosphatase (ALP), presence of anti-mitochondrial antibody (AMA), or histologic evidence of nonsuppurative destructive cholangitis. AMA is the most specific marker. Liver biopsy is reserved for AMA-negative cases or when overlap syndromes are suspected.
Treatment
Ursodeoxycholic acid is the standard of care to slow disease progression. Obeticholic acid is a second-line agent for those with inadequate response. Liver transplant is the definitive treatment for decompensated cirrhosis or intractable pruritus.
Prognosis
Disease progression leads to cirrhosis and increased risk of hepatocellular carcinoma. Patients require surveillance with abdominal ultrasound every 6 months and monitoring for osteoporosis due to malabsorption of fat-soluble vitamins.
Differential Diagnosis
Primary Sclerosing Cholangitis: associated with IBD and p-ANCA
Autoimmune Hepatitis: elevated IgG and smooth muscle antibodies
Drug-induced cholestasis: history of new medication initiation
Secondary biliary cirrhosis: presence of mechanical bile duct obstruction
Viral hepatitis: positive serology for HBV or HCV